Clinical trials: Movement Abnormalities
Parkinson Disease
50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease
Background: In transcranial magnetic stimulation (TMS), a device creates a short-lasting magnetic field which induces an electric current in the brain leading to a change in the activity of brain cells.
- Trial name
- NCT00977184
- Testing
- 50 HZ Repetitive TMS
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Tourette Syndrome
Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome
This study will evaluate the clinical efficacy of 1 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the supplementary motor area (SMA) in Tourette's Syndrome (TS) patients who have not fully responded to…
- Trial name
- TMS (NCT00529308)
- Testing
- Transcranial Magnetic Stimulation (active)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Parkinson Disease
Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
This is an open-label, prospective post marketing surveillance study to be performed in Sweden. Only data of patients idiopathic PD should be documented, in whom the treating physician plans to initiate a pharmacotherapy with PPX…
- Trial name
- NCT01097421
- Testing
- Pramipexole Extended Release
- Volunteers
- 329 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
OpiCapone Effect on Motor Fluctuations and pAiN
The aim of this study is to investigate the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson's disease (PD) patients with…
- Trial name
- OCEAN (NCT04986982)
- Testing
- Opicapone 50 mg
- Where
- United Kingdom
- Volunteers
- 144 people
- Sponsor
- Bial - Portela C S.A.
Tourette Syndrome
Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
This is a Phase 2b, multicenter, open-label study to evaluate the safety and tolerability of optimized doses of NBI-98854 administered once daily for 24 weeks in pediatric subjects with Tourette Syndrome.
- Trial name
- NCT03444038
- Testing
- Valbenazine
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 85 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease, Brain Stimulation
Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder and affects approximately 1 million people in the United States with total annual costs approaching 11 billion dollars.
- Conditions
- Parkinson Disease, Brain Stimulation, Cerebellum
- Trial name
- NCT04046055
- Testing
- Transcranial direct current stimulation at 2 mA, Transcranial direct current stimulation at 4 mA
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Thorsten Rudroff